Sign in to tag this notice and share notes on it with your team.
Winston AI writes a plain-English brief of every opportunity — what the buyer wants, and what affects whether to bid. It's free in every Scout workspace. Sign in to see it.
NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East.
Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months.
Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
| Lot | Title | Value |
|---|---|---|
| 1 | Lot 1 | — |
| 2 | Lot 2 | — |
| Title | Supplier | Value | Awarded |
|---|---|---|---|
| Lot 1 - CM/PHR/25/5730/01 - NHS Branded Medicines Tranche A for Midlands & East | AVENTIS PHARMA LIMITED t-a Sanofi | £665,389,588 | 14 Jun 2026 |
| Lot 2 - CM/PHR/25/5730/02 - Natalizumab for London & South of England | BIOGEN IDEC LIMITED | £35,312,548 | 14 Jun 2026 |